Passa al contenuto
Merck
Tutte le immagini(2)

Documenti

05-796

Sigma-Aldrich

Anti-Akt1/PKBα Antibody, clone AW24, rabbit monoclonal

clone AW24, Upstate®, from rabbit

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Origine biologica

rabbit

Livello qualitativo

100

Forma dell’anticorpo

purified antibody

Tipo di anticorpo

primary antibodies

Clone

AW24, monoclonal

Reattività contro le specie

human, mouse, rat

Produttore/marchio commerciale

Upstate®

tecniche

immunoprecipitation (IP): suitable
western blot: suitable

Isotipo

IgG

N° accesso NCBI

NM_005163

N° accesso UniProt

P31749

Condizioni di spedizione

dry ice

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... AKT1(207)

Specificità

Akt1/PKBα

Immunogeno

Peptide (C-RPHFPQFSYSASGTA) corresponding to the C-terminal (residues 466-480) of rat Akt1/PKBα

Applicazioni

Detect Akt1/PKBα using this Anti-Akt1 Antibody, clone AW24 validated for use in IP & WB.
Research Category
Signaling
Research Sub Category
PI3K, Akt, & mTOR Signaling

Qualità

routinely evaluated by immunoblot on RIPA lysates from human HEK293 cells

Descrizione del bersaglio

~60kDa

Stato fisico

0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide before the addition of glycerol to 30%
Format: Purified
Protein A purified

Stoccaggio e stabilità

2 years at -20°C

Note legali

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Motore di ricerca dei prodotti.

Raccomandato

N° Catalogo
Descrizione
Determinazione del prezzo

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Sumiko Watanabe et al.
Cytotechnology, 71(1), 219-229 (2019-01-04)
A proposed mechanism underlying the effect of bacillus Calmette-Guérin (BCG) treatment for bladder cancer cells is as follows: BCG-induced crosslinking of cell-surface receptors results in the activation of signaling cascades, including cell-cycle regulators. However, the clinical significance of cell-cycle regulators
Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation.
Choi, JC; Muchir, A; Wu, W; Iwata, S; Homma, S; Morrow, JP; Worman, HJ
Science Translational Medicine null
Santhanalakshmi Sundaramurthy et al.
Neuropharmacology, 113(Pt A), 281-292 (2016-11-05)
Kappa opioid receptor (KOR) agonists produce dysphoria and psychotomimesis. While KOR agonists produce pro-depressant-like effects, KOR antagonists produce anti-depressant-like effects in rodent models. The cellular mechanisms and downstream effector(s) by which KOR ligands produce these effects are not clear. KOR
Chih-Jen Cheng et al.
Journal of the American Society of Nephrology : JASN, 22(3), 460-471 (2011-03-01)
WNK kinases stimulate endocytosis of ROMK channels to regulate renal K+ handling. Phosphatidylinositol 3-kinase (PI3K)-activating hormones, such as insulin and IGF 1, phosphorylate WNK1, but how this affects the regulation of ROMK abundance is unknown. Here, serum starvation of ROMK-transfected
Toshitaka Uehara et al.
Cytotechnology, 75(1), 49-62 (2023-01-31)
The standard treatment for non-muscle-invasive bladder cancer is intravesical Bacillus Calmette-Guérin (BCG) therapy, which is considered the only intravesical therapy that reduces the risk of progression to muscle-invasive cancer. BCG unresponsiveness, in which intravesical BCG therapy is ineffective, has become
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.